Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SGX:T14)

Singapore flag Singapore · Delayed Price · Currency is SGD · Price in USD
2.890
+0.340 (13.33%)
Oct 31, 2025, 5:10 PM SGT
13.33%
Market Cap5.46B
Revenue (ttm)972.89M
Net Income (ttm)648.69M
Shares Outn/a
EPS (ttm)0.84
PE Ratio8.41
Forward PEn/a
Dividend0.23 (8.96%)
Ex-Dividend DateJun 25, 2025
Volume614,500
Average Volume209,160
Open2.750
Previous Close2.550
Day's Range2.750 - 2.920
52-Week Range1.990 - 3.130
Betan/a
RSI58.23
Earnings DateOct 31, 2025

About SGX:T14

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited, together with its subsidiaries, produces and sells traditional Chinese medicine, western medicine, and other products primarily in the People’s Republic of China. The company manufactures and sells of biochemical pharmaceutical products. It also engages in research and development of chinese patent medicines, chemical raw materials and preparations, and nutritional supplements. In addition, the company is involved in pharmaceutical and drug retail business. Further, it offers Suxiao ... [Read more]

Sector Healthcare
Founded 1981
Employees 4,619
Stock Exchange Singapore Exchange
Ticker Symbol T14
Full Company Profile

Financial Performance

In 2024, SGX:T14's revenue was 7.31 billion, a decrease of -11.14% compared to the previous year's 8.22 billion. Earnings were 2.23 billion, an increase of 125.94%.

Financial numbers in CNY Financial Statements

News

There is no news available yet.